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A B S T R A C T
Myeloid Sarcoma (MS) is a rare malignancy that can present as an isolated disease or more frequently in as-
sociation with or following acute myeloid leukemia or other myeloid neoplasms and rarely following myeloﬁ-
brosis.
Since molecular pathogenesis and prognostic factors of MS are not well understood, its prognosis remains
poor even in the era of novel agents and target therapies.
We report the case of a patient with MS following myeloﬁbrosis with multiple subcutaneous, cutaneous and
muscle localizations; the latter has been reported in the literature as anecdotal. In this way we aimed to enhance
the understanding of this disease.
1. Introduction
Myeloid Sarcoma (MS) is a rare entity characterized by the pro-
liferation of immature myeloid cells in extramedullary sites. The 2008
WHO Classiﬁcation of Tumours of Haematopoietic and Lymphoid
Tissues and its updated 2016 version clariﬁed the diagnosis of MS as “a
tumor mass consisting of myeloid blasts with or without maturation
occurring at an anatomic site other than the bone marrow” [1,2]. A
predilection for males (male: female ratio = 1.2:1) is reported, with a
median age at diagnosis of 56 years [3].
Myeloid sarcoma can be observed as a de novo malignancy (without
leukemic presentation in peripheral blood and bone marrow), during
the course of acute myeloid leukemia (AML), aﬀecting 2.5–9% of all
AML patients, myelodysplastic syndromes (MDS) or myeloproliferative
neoplasms (MPNs, both chronic myeloid leukemia and BCR-ABL1-ne-
gative MPNs) or MDS/MPNs such as chronic myelomonocytic leukemia
(CMML); it has also been described as a relapse in a previous AML
[1,4,5].
Myeloid sarcoma most commonly involve lymph nodes, skin, soft
tissues and testes. In less than 10% of cases the presentation may be at
multiple anatomical sites.
Since MS can present at multiple sites that can be often clinically
silent, Positron Emission Tomography (FDG-PET) has been demon-
strated as a useful tool in detecting extramedullary AML and, as
previously revealed, it should be used both in diagnosis and after
treatment, in order to evaluate response to therapy [6]
Diﬀerential diagnosis should be made with other hematological
malignancies involving lymph nodes, skin and other extra-hematolo-
gical sites, such as B-cell lymphomas, cutaneous or peripheral T-cell
lymphomas [3].
As far as genetic/molecular lesions are concerned, MS does not
diﬀer from AML. In fact, chromosomal aberrations are detected by
Fluoresce in Situ Hybridization (FISH) and/or conventional cytoge-
netics in about half of cases and include:−7, +8, MLL-rearrangement,
inv(16), +4, −16/16q-, 5q-, 20q- and +11. About 16% of patients
carries nucleophosmin (NPM1) mutations, as shown by aberrant cyto-
plasmic NPM1 expression [1]. Furthermore, about 20–30% of MS,
especially those evolving from AML, harbor mutations of FMS-like
tyrosine kinase 3 (FLT3) gene, commonly Internal Tandem Duplications
(ITD) [7].
Here we report an unusual case of MS presenting with multiple skin,
subcutaneous and muscular lesions in a patient aﬀected by primary
myeloﬁbrosis (PMF) which was diagnosed approximately 16 years be-
fore.
2. Case report
A 53-years-old man was diagnosed with pre-ﬁbrotic PMF in 2000 in
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another Hospital, because of persistent, severe thrombocytosis.
Conventional cytogenetic analysis showed a normal male karyotype.
Consequently, he was initially treated with low-dose acetylsalicylic acid
and hydroxyurea. Ten years later, he was admitted to our Institution
and molecular evaluations were done, demonstrating the absence of
JAK2V617F and MPL mutations, as well as BCR-ABL1 fusion gene.
After one year of follow-up, hematological investigations revealed
severe anemia (hemoglobin level of 7.6 g/dL). Since the negativity of
further diagnostic evaluations, a new bone marrow biopsy was per-
formed, revealing an increase in bone marrow ﬁbrosis (MF-2, according
to the EUMNET consensus) [7]. Consequently, the patient stopped as-
suming hydroxyurea and was started on corticosteroids and transfu-
sional supportive therapy. Further molecular tests showed a type-2
mutation of the CALR gene (ins5-bp). At that point, MySEC score [8]
was retrospectively evaluated and it resulted Intermediate − 1.
In September 2016 the patient presented with asymptomatic sub-
cutaneous nodules on the chest wall, neck and left arm, with a max-
imum diameter of 2 cm; at ultrasound examination they were hy-
poechogenic irregular nodules that invaded the surrounding muscle
tissue. Furthermore, a FDG-PET detected multiple metabolically active
lesions in soft tissues (SUV max 4.5) on right and left shoulder, chest
wall, back, epigastric region and legs (Fig. 1).
Finally, a biopsy of a sub-cutaneous lesion was performed and the
histopathologic examination revealed the presence of a granulocytic
sarcoma. Immunohistochemistry showed that the majority of pro-
liferating cells expressed CD34, CD43, CD117(+/-), CD45/LCA(+/-)
antigens, but were negative for CD20, CD3, CD30, CD68/kp1, CD68R
antigens and for myeloperoxidase. Immunohistochemical positivity of
B
A
Fig. 1. (A). FDG-PET detection of multiple metabolically active lesions on soft tissues on right and left shoulder, chest wall, back, epigastric region and legs (arrows). (B). FGD post
induction and consolidation chemotherapy showing persistence of one metabolic active subcutaneous lesion on left arm (arrow).
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NPM1 with nuclear dislocation was also present, whereas FLT3 muta-
tions were not found (Fig. 2). Subsequently a new bone marrow biopsy
showed leukemic transformation of PMF, with a normal male kar-
yotype.
The patient underwent “3+7″ induction chemotherapy with dau-
norubicin and cytarabine, followed by consolidation treatment with
three courses of intermediate dose Ara-C, obtaining complete mor-
phologic and immunophenotypic remission with typical features of
PMF, clinical disappearance of subcutaneous nodules, but persistence of
FDG-PET pathological uptake on both arms. As the pathological uptake
on the right arm was in the area of a previous venous access (Fig. 1), we
decided to perform radiotherapy (RT) on the contralateral arm.
3. Discussion
The natural history of PMF is characterized by the possibility of
blastic transformation in approximately 20% of all the cases [9]. Sev-
eral factors might predict leukemic transformation, including percen-
tage of circulating blasts, low platelets count and the presence of an
unfavorable karyotype. At a molecular level, it is well known that PMF
patients harboring type-1 CALR mutation have a more indolent clinical
course compared to other mutational proﬁles, especially considering
those cases without known driver mutations (i.e. triple-negative pa-
tients). Furthermore, patients carrying high risk mutations, namely
ASXL1, IDH1-2, EZH2 and SRSF2 show a reduced leukemia-free survival
[10–12].
Nevertheless, factors that could be associated with MS development
and predict a possible evolution of PMF are poorly understood, because
of the rarity of these conditions.
Only few cases of MS have been reported in the literature so far
[4,5], and even fewer cases developed synchronous or metachronous
PMF.
Regarding MS pathogenesis, aberrant tropism of leukemic blasts for
extramedullary tissues is poorly understood. It is clear that homing of
tumor cells is a complex phenomenon determined by several factors,
including the expression of chemokine receptors and adhesion mole-
cules that is already under control of many genetic and epigenetic
mechanisms [13]. To address the hypothesis that MS is genetically si-
milar to AML, in 2015 Li et al. performed next-generation sequencing
analysis in six cases of isolated MS [11], and conﬁrmed the frequent
occurrence of FLT3 and NPM1 mutations. Furthermore, they identiﬁed
other mutations in a broad spectrum of AML associated genes, including
tumor suppressors (WT1), epigenetic modiﬁers (TET2, ASXL1, EZH2),
spliceosome proteins (SF3B1) and tyrosine kinase (FLT3 and KIT). With
regard to KIT mutation, interestingly, Li et al. showed the presence of
somatically acquired mutation KITM541L in four of the six analyzed
patients, being the latter previously associated with a variety of neo-
plasms including hematologic malignancies such as CML or Chronic
Eosinophilic Leukemia [11, 14, 15].
Concerning MS prognosis, it varies according to the diﬀerent
background of MS formation. In particular, it seems clear that isolated
MS presents a more favorable clinical course than cases with either
concomitant AML or at AML relapse. In addition, Lan et al. and
Kawamoto et al. showed a more aggressive clinical course in MS fol-
lowing MDS or MPN [5,16].
Furthermore, the authors showed that immunohistochemical ex-
pression of CXCR4, that could be implicated in MS pathogenesis, was a
poor prognostic factor for overall survival (OS) [5].
CXCR4 over-expression in cancer is thought to be associated with
chemotaxis, invasion, angiogenesis and proliferation. It has also been
Fig. 2. (A-B). Excisional biopsy of a cutaneous lesion revealing the presence of a diﬀuse inﬁltration of proliferating elements with a blastic habit, involving also the subcutaneous fat and
muscle tissues. (C). Immunohistochemistry showing that the majority of proliferating cells expressed CD34 antigen. (D). Immunohistochemical positivity of NPM1 with nuclear dis-
location.
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demonstrated that in hematological malignancies, the over-expression
of CXCR4 is related to a shortened progression-free and overall survival,
in particular in AML patients [13,17].
This genomic complexity of MS implies that this malignancy pre-
sents a poor response to therapy. In fact, as recently reported by
Lazzarotto et al., the complete remission rate of a cohort of 48 MS
treated with various intensive induction chemotherapy regimens (in-
cluding ﬂudarabine-based, anthracicline and cytarabine containing
treatments) was about 45%, and the median (OS) of the entire popu-
lation was 16.7 months, with a 5-year OS of 33%. This outcome was
favorably inﬂuenced by response to ﬁrst induction chemotherapy and
was better in patients receiving allogeneic stem cell transplantation
[18].
Demethylating agents may have a role in the therapeutic scenario of
MS patients, in particular for those who are ineligible for intensive
treatments, although the number of cases treated is still low, due to the
rarity of this disease. Recently, Gornicec et al. described three MS cases
treated with decitabine achieving a good response [19]. Two other
cases with durable remission were previously described [20,21].
Little is still known about the eﬃcacy of novel agents, in particular
FLT3-inhibitors in the treatment of this rare malignancy.
Radiotherapy may also be useful in the treatment of MS. In fact, this
therapeutic approach provides timely symptom palliation with modest
radiation doses and minimal toxicity [22]. Some case-series reported
that RT for consolidation in addition to systemic chemotherapy was
associated with a better outcome in patients with MS [23]. Consolida-
tion with RT has also been suggested in patients with incomplete re-
sponse to chemotherapy [24].
4. Conclusion
MS, and in particular those following MF, are a rare entity. Indeed,
in the two largest patient series reported so far, only few subjects had a
diagnosis of MS concurrent or subsequent to MF [4,5]. Furthermore,
muscle involvement is reported as anecdotal. Since its pathogenesis and
genomic landscape are not well understood, the prognosis remains
dismal, even in the novel agent era. Therefore, each case description is
fundamental to provide a better knowledge about this rare malignancy.
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